A Phase 2 Clinical Trial of STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancers
- Each treatment cycle lasts 4 weeks during which time the study drug will be
administered for three consecutive weeks followed by 1 week of no study drug. STA-9090
will be given by intravenous infusion.
- Participants will come to the clinic on Days 1, 8, and 15 of all cycles. At these
visits, the following tests and procedures will be performed: Review of current
medications and any side effects experienced; Performance status evaluation; Physical
examination; Vital signs; Routine blood tests; CT scan of the chest, abdomen, and
pelvis (every 2 cycles) and Optional FDG-PET scan (every 2 cycles).
- Participants may remain on this research study for as long as their cancer is
responding to the study drug and they are not experiencing any severe side effects.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To evaluate the efficacy of STA-9090 in patients who have progressed through prior 1st-line treatment for esophagogastric cancer, as measured by overall response rate.
Eunice Kwak, MD, PhD
Massachusetts General Hospital
United States: Food and Drug Administration
|Beth Israel Deaconess Medical Center||Boston, Massachusetts 02215|
|Dana-Farber Cancer Institute||Boston, Massachusetts 02115|
|Massachusetts General Hospital||Boston, Massachusetts 02114-2617|